Related Experiment Video
Updated: Oct 16, 2025

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
Published on: April 30, 2020
First Co-morbidity of Lophomonas blattarum and COVID-19 Infections: Confirmed Using Molecular Approach
Maryam Nakhaei1, Mahdi Fakhar2, Ali Sharifpour3,4
1Toxoplasmosis Research Center, School of Medicine, Communicable Diseases Institute, Iranian National Registry Center for Lophomoniasis and Toxoplasmosis, Mazandaran University of Medical Sciences, Km 18, Farah-Abad Road, PO Box 48471-91971, Sari, Iran.
Introduction:
Lophomoniasis is caused by Lophomonas spp., a new emerging protozoan, which commonly affects the human lower respiratory tract. The Lophomonas parasite mostly lives commensally in the hindgut of cockroaches.
Case Presentation:
We present the case of a 33-year-old woman, 30 weeks pregnant, who had severe COVID-19. She was intubated upon admission and began the routine COVID-19 treatment. To rule out possible super infection dual with COVID-19, microscopic examination of the patient's mini-bronchoalveolar lavage (mini-BAL) specimen, revealed L. blattarum, which was identified by the SSU rRNA-PCR and sequencing approaches (accession number: MZ093069). According to that, the patient was treated successfully with metronidazole.
Conclusion:
To prevent serious complications, lophomoniasis should be listed in co-morbidity cases of COVID-19 infection during the COVID-19 pandemic worldwide. To the best of our knowledge, this is the first co-infection of Lophomonas blattarum and COVID-19 in the world which has been confirmed using a molecular approach.
Related Concept Videos
Applications of Molecular Taxonomy
MALDI-TOF Mass Spectrometry
Matrix-assisted laser desorption ionization (MALDI) is a commonly...
Modern Molecular Taxonomy

